Sage Journals: Discover world-class research

Abstract

Background:

Treatment with natalizumab, a humanized monoclonal antibody against alpha4beta1 integrin, is associated with an increase in lymphoid progenitor cells and B cells in peripheral blood.

Objective:

The objective of this study was to examine the impact of natalizumab therapy on serum levels of total IgG, IgA and IgM in patients with multiple sclerosis (MS).

Methods:

In two independent cross-sectional patient cohorts, serum levels of IgG, IgA and IgM were compared between patients treated with natalizumab and those not receiving natalizumab. Further, serum levels of IgG, IgA and IgM before and during natalizumab treatment were compared in two longitudinal patient cohorts.

Results:

In patients treated with natalizumab, serum IgM and IgG levels were significantly lower compared with therapy naïve patients (p<0.0001). IgM levels significantly decreased after initiation of natalizumab treatment in both longitudinal patient cohorts (p<0.01). Moreover, patients treated with natalizumab showed a time-dependent decrease in IgM levels during the first 2 years of treatment.

Conclusion:

Natalizumab treatment leads to a significant decrease in serum IgM and IgG levels in patients with MS. IgM levels decrease with treatment duration during the first 2 years of treatment. These findings might support the hypothesis that natalizumab interferes with homing of B cells, possibly leading to impaired differentiation into plasma cells and subsequently disturbed immunoglobulin synthesis.

Keywords

Multiple sclerosis natalizumab alpha4beta1 integrin B cell homing immunoglobulin M immunoglobulin G

Get full access to this article

View all access options for this article.

References

Fabbri

Bianchi

Fumagalli

. Regulation of lymphocyte traffic by adhesion molecules. Inflamm Res 1999; 48: 239–246.

Elices

Osborn

Takada

. VCAM-1 on activated endothelium interacts with the leukocyte integrin VLA-4 at a site distinct from the VLA-4/fibronectin binding site. Cell 1990; 60: 577–584.

Alon

Kassner

Carr

. The integrin VLA-4 supports tethering and rolling in flow on VCAM-1. J Cell Biol 1995; 128: 1243–1253.

Yednock

Cannon

Fritz

. Prevention of experimental autoimmune encephalomyelitis by antibodies against alpha 4 beta 1 integrin. Nature 1992; 356: 63–66.

Polman

O’Connor

Havrdova

. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med 2006; 354: 899–910.

Zohren

Toutzaris

Klarner

. The monoclonal anti-VLA-4 antibody natalizumab mobilizes CD34+ hematopoietic progenitor cells in humans. Blood 2008; 111: 3893–3895.

Bonig

Wundes

Chang

. Increased numbers of circulating hematopoietic stem/progenitor cells are chronically maintained in patients treated with the CD49d blocking antibody natalizumab. Blood 2008; 111: 3439–3441.

Cyster

. Integrin-dependence of lymphocyte entry into the splenic white pulp. J Exp Med 2003; 197: 353–361.

Belnoue

Tougne

Rochat

. Homing and adhesion patterns determine the cellular composition of the bone marrow plasma cell niche. J Immunol 2012; 188: 1283–1291.

10.

Carrasco

Batista

. B-cell activation by membrane-bound antigens is facilitated by the interaction of VLA-4 with VCAM-1. EMBO J 2006; 25: 889–899.

11.

Cyster

. Integrin-mediated long-term B cell retention in the splenic marginal zone. Science 2002; 297: 409–412.

12.

Krumbholz

Meinl

Kumpfel

. Natalizumab disproportionately increases circulating pre-B and B cells in multiple sclerosis. Neurology 2008; 71: 1350–1354.

13.

Planas

Jelcic

Schippling

. Natalizumab treatment perturbs memory- and marginal zone-like B-cell homing in secondary lymphoid organs in multiple sclerosis. Eur J Immunol 2012; 42: 790–798.

14.

Silvy

Altevogt

Mondiere

. A role for the VLA-4 integrin in the activation of human memory B cells. Eur J Immunol 1997; 27: 2757–2764.

15.

Berlin-Rufenach

Otto

Mathies

. Lymphocyte migration in lymphocyte function-associated antigen (LFA)-1-deficient mice. J Exp Med 1999; 189: 1467–1478.

16.

Berlin

Bargatze

Campbell

. alpha 4 integrins mediate lymphocyte attachment and rolling under physiologic flow. Cell 1995; 80: 413–422.

17.

Finke

Acha-Orbea

Mattis

. CD4+CD3− cells induce Peyer’s patch development: Role of alpha4beta1 integrin activation by CXCR5. Immunity 2002; 17: 363–373.

18.

Vinuesa

Tangye

Moser

. Follicular B helper T cells in antibody responses and autoimmunity. Nat Rev Immunol 2005; 5: 853–865.

19.

Mora

von Andrian

. Differentiation and homing of IgA-secreting cells. Mucosal Immunol 2008; 1: 96–109.

20.

Villar

Garcia-Sanchez

Costa-Frossard

. Immunological markers of optimal response to natalizumab in multiple sclerosis. Arch Neurol 2012; 69: 191–197.

21.

Corcione

Casazza

Ferretti

. Recapitulation of B cell differentiation in the central nervous system of patients with multiple sclerosis. Proc Natl Acad Sci U S A 2004; 101: 11064–11069.

22.

McMillan

Longmire

Yelenosky

The effect of corticosteroids on human IgG synthesis. J Immunol 1976; 116: 1592–1595.

23.

Settipane

Pudupakkam

McGowan

. Corticosteroid effect on immunoglobulins. J Allergy Clin Immun 1978; 62: 162–166.

24.

Posey

Nelson

Branch

. The effects of acute corticosteroid therapy for asthma on serum immunoglobulin levels. J Allergy Clin Immun 1978; 62: 340–348.

25.

Freeman

Crassini

Best

. Immunoglobulin G (IgG) subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukaemia. Leuk Lymphoma 2012.

26.

Freeman

Crassini

Best

. Immunoglobulin G subclass deficiency and infection risk in 150 patients with chronic lymphocytic leukemia. Leuk Lymphoma. 2013; 54: 99–104.

27.

Hopfinger

Plessl

Grisold

. Progressive multifocal leukoencephalopathy after rituximab in a patient with relapsed follicular lymphoma and low IgG levels and a low CD4+ lymphocyte count. Leuk Lymphoma 2008; 49: 2367–2369.

Supplementary Material

Please find the following supplemental material available below.

For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.

For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.

0.00 MB

0.56 MB

Natalizumab treatment decreases serum IgM and IgG levels in multiple sclerosis patients